1. Home
  2. WLYB vs TNGX Comparison

WLYB vs TNGX Comparison

Compare WLYB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Wiley & Sons Inc.

WLYB

John Wiley & Sons Inc.

HOLD

Current Price

$32.30

Market Cap

1.6B

ML Signal

HOLD

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$12.70

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLYB
TNGX
Founded
1807
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WLYB
TNGX
Price
$32.30
$12.70
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.33
AVG Volume (30 Days)
2.2K
2.9M
Earning Date
03-05-2026
02-26-2026
Dividend Yield
4.39%
N/A
EPS Growth
N/A
N/A
EPS
1.87
N/A
Revenue
$1,665,756,000.00
$66,501,000.00
Revenue This Year
$0.02
$52.63
Revenue Next Year
$2.32
N/A
P/E Ratio
$15.52
N/A
Revenue Growth
N/A
53.29
52 Week Low
$29.79
$1.03
52 Week High
$46.81
$13.46

Technical Indicators

Market Signals
Indicator
WLYB
TNGX
Relative Strength Index (RSI) 46.18 60.67
Support Level $29.79 $12.17
Resistance Level $32.65 $13.18
Average True Range (ATR) 0.34 0.75
MACD 0.02 -0.00
Stochastic Oscillator 57.28 80.73

Price Performance

Historical Comparison
WLYB
TNGX

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: